



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

LAWRENCE TAMARKIN ET AL.

Serial No. **08/215,030**

Filed: **MARCH 18, 1994**

**For: COMPOSITION AND METHOD FOR
REDUCING TOXICITY OF BIOLOGICALLY-
ACTIVE FACTORS**

Art Unit:

RECEIVED
JUN 28 1994
GROUP 1800

**INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. § 1.56 AND § 1.97**

Commissioner of Patents & Trademarks

Washington, DC 20231

Sir:

Pursuant to 37 C.F.R. § 1.56 and § 1.97, Applicant herewith discloses art to the Patent Office which Applicants believe a reasonable Examiner may consider important in deciding whether to allow the above-referenced patent application to issue as a patent.

I. Art Disclosed By Applicants

No copies of the below-listed art are enclosed because they have already been made of record in the prior related patent application.


The following art was disclosed by the Applicants in an Information Disclosure Statement filed June 8, 1993, in prior related patent application Serial No. 08,033,385, pending.

US Patents

- 1) 4,740,589 to Moreno
- 2) 3,145,144 to Ando

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner of Patents and Trademarks, Washington, DC 20231, on 6/15/94.

James Dean Johnson - Reg. No. 31,771



Serial No. 08/215,030

- 3) 3,269,912 to Grase
- 4) 3,577,523 to Stolar
- 5) 4,069,313 to Woodhour et al.
- 6) 3,983,228 to Woodhour et al.
- 7) 3,531,565 to Webb et al.
- 8) 3,149,036 to Woodhour et al.
- 9) 3,399,263 to Strazdins et al.
- 10) 4,657,763 to Finkelstein
- 11) 4,330,530 to Baker
- 12) 4,339,437 to Rosenberg et al.
- 13) 4,177,263 to Rosenberg et al.
- 14) 4,053,587 to Davidson et al.
- 15) 4,977,286 to Nicolaou et al.
- 16) 5,017,687 to Vahlne et al.
- 17) 4,812,556 to Vahlne et al.
- 18) 4,880,750 to Francoeur
- 19) 5,035,995 to Taguchi et al.
- 20) 4,882,423 to Taguchi et al.
- 21) 4,906,564 to Lyon et al.
- 22) 5,019,497 to Olsson
- 23) 4,753,873 to Beltz et al.
- 24) 4,744,760 to Molday
- 25) 4,624,923 to Margel
- 26) 3,651,211 to Gillchriest et al.
- 27) 2,768,958 to Stewart et al.
- 28) 2,785,153 to Locke et al.
- 29) 3,819,820 to Lorina et al.

RECEIVED
JUN 28 1994
GROUP 1800



Serial No. 08/215,030

RECEIVED
JUN 28 1994
GROUP 1800

II. Art cited by an examiner

No copies of the below-listed art are enclosed because they have already been made of record in the prior related patent application.

The following art was cited by an Examiner in an Office Action mailed August, 23, 1993, in prior related patent application Serial No. 08/033,385, pending.

US Patent

- 30) 5,112,606 to Shiosaka et al.

The following art was cited by an Examiner in a Final Office Action mailed April 14, 1994, in prior related patent application Serial No. 08/033,385, pending.

Foreign Patent

- 31) WO 9102078 PCT

Publications

32) Fraker, et al., "Passive Immunization Against Tumor Necrosis Factor Partially Abrogates Interleukin 2 Toxicity," *The Journal of Experimental Medicine*, Vol. 170, pages 1015-1020 (1989).

33) Lanzavecchia, "Identifying Strategies for Immune Intervention," *Science*, Vol. 260, pages 937-944 (1993).

III. The Cited Art is as Follows:

Copies of the below-listed art are enclosed.

Publications

34) Paciotti, et al., "Interleukin 2 differentially effects the proliferation of a hormone-dependent and a hormone-independent human breast cancer cell line *in vitro* and *in vivo*," *Anti-Cancer Research*, Vol. 8, pages 1233-1240 (1988).

35) Paciotti, et al., "Interleukin 1 differentially synchronizes estrogen dependent and estrogen-independent human breast cells in G₀/G₁ phase of the cell cycle," *Anti-Cancer Research*, vol. 11, pages 25-32 (1991).

36) Paciotti, et al., "Interleukin 1 directly regulates hormone-dependent human breast cancer cell proliferation *in vitro*," *Mol. Endocrinol.*, Vol. 2, pages 459-464 (1988).

37) Coulombe et al., "Cytochemical Demonstration of Increased Phospholipid Content in Cell Membranes in Chlorpromazine-induced Phospholipidosis," *Journal of Histochemistry and Cytochemistry*, Vol. 37, No. 2, pages 139-147 (1989).


38) Hashimoto et al., "Action Site of Circulating Interleukin-1 on the Rabbit Brain," *Brain Research*, Vol. 540, pages 217-223 (1991).

39) Ohmann et al., "Expression of Tumor Necrosis Factor- α Receptors on Bovine Macrophages, Lymphocytes and Polymorphonuclear Leukocytes, Internalization of Receptor-Bound Ligand, and Some Functional Effects," *Lymphokine Research*, Vol. 9, No. 1, pages 43-58 (1990).

The citation of art contained on the accompanying Form PTO-1449 is in no way to be construed as an admission that any of said art is a suitable reference against the above-referenced application nor should this citation act as a waiver of any rights to overcome said art which may be available to the applicant.

Applicant respectfully requests that the Examiner review the foregoing references and that the references be made of record in the prosecution history of the application.

Respectfully submitted,


By: James Dean Johnson
Reg. No. 31,771

JONES & ASKEW
37th Floor
191 Peachtree Street, N.E.
Atlanta, GA 30303-1769
(404) 818-3700
Our Docket: 01994-0021